Related Experiment Videos
Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease
1Service de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpétrière, Paris, France.
Insights
Aspirin and clopidogrel are effective antiplatelet agents for preventing atherothrombotic events. Clopidogrel demonstrated superior risk reduction for myocardial infarction compared to aspirin in high-risk patients.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Trials
Background:
- Atherothrombosis is a primary cause of cardiovascular events like heart attack and stroke, leading to significant mortality.
- Platelet inhibitors are crucial in managing and preventing ischemic complications associated with atherosclerosis.
Purpose of the Study:
- To evaluate the efficacy of antiplatelet agents, particularly clopidogrel, in preventing atherothrombotic events.
- To compare the effectiveness of clopidogrel against aspirin in high-risk patient populations.
Main Methods:
- Review of clinical trials including the Antiplatelet Trialists' Collaboration, Ticlopidine Aspirin Stroke Study (TASS), Swedish Ticlopidine Multicentre Study (STIMS), and Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE).
- Analysis of secondary prevention strategies for ischemic stroke, peripheral arterial disease, and acute coronary syndromes.
Main Results:
- Aspirin effectively reduces the risk of stroke, myocardial infarction (MI), or vascular death in atherosclerotic patients.
- Clopidogrel showed a significant advantage over aspirin in secondary stroke prevention and was highly effective in peripheral arterial disease.
- The CAPRIE trial indicated clopidogrel provided an 8.7% relative risk reduction for ischemic events compared to aspirin, with a notable 19% reduction in fatal and nonfatal MI in severe cases.
Conclusions:
- Antiplatelet therapy, including aspirin and clopidogrel, is vital for managing atherothrombosis.
- Clopidogrel offers significant benefits over aspirin for high-risk patients, particularly in reducing myocardial infarction.
- Combination antiplatelet therapy may be necessary for complex cardiovascular conditions like coronary disease and following stent placement.
Abstract:
Atherothrombosis is the major underlying cause of acute coronary syndromes, ischemic stroke, and peripheral artery disease, and thus is the leading cause of death and disability in Western countries. Platelet inhibitors play a major role in preventing these ischemic complications. There is strong evidence from the Antiplatelet Trialists' Collaboration meta-analysis that aspirin reduces the combined risk of stroke, myocardial infarction (MI), or vascular death in atherosclerotic patients. The Ticlopidine Aspirin Stroke Study (TASS) compared aspirin and ticlopidine in the secondary prevention of high-risk patients after ischemic stroke and demonstrated a significant advantage for ticlopidine over aspirin. In peripheral arterial disease, the Swedish Ticlopidine Multicentre Study (STIMS) showed that ticlopidine was very effective against placebo. Intravenous antiplatelet agents, such as abciximab, tirofiban, and eptifibitide were also proven effective in acute coronary syndromes and unstable angina. In the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial, clopidogrel was compared with aspirin in patients with symptomatic atherothrombosis regardless of the initial localization of the ischemic event (coronary, cerebral, or peripheral). The efficacy of clopidogrel based on the first occurrence of ischemic stroke, MI, or vascular death showed a relative risk reduction of 8.7% over and above the 25% reduction currently accepted with aspirin (p < 0.05). The greatest benefit of clopidogrel was in the reduction of fatal and nonfatal MI in the most severe groups of patients, providing a 19% relative risk reduction (p = 0.008). The recent disappointing results obtained with oral glycoprotein IIb/IIIa receptor blocking agents may emphasize the need for other antiplatelet combination therapy, such as aspirin-clopidogrel, in coronary disease, stents, stroke, and possibly atherothrombosis in high-risk patients.